# A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease

> **NCT02726386** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **NeuroDerm Ltd.** · enrollment: 214 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** ND0612

## Key facts

- **NCT ID:** NCT02726386
- **Lead sponsor:** NeuroDerm Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-05-04
- **Primary completion:** 2019-09-09
- **Final completion:** 2027-02
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02726386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02726386, "A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02726386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*